Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02705924
Other study ID # BRACAVENIR
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date April 2016
Est. completion date September 14, 2021

Study information

Verified date November 2021
Source Centre Jean Perrin
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Young female counselees (18-40 years) belonging to HBOC families with a known mutation on BRCA-genes or not, receive a lot of information regarding their cancer risk. Information sources are numerous and sometimes contradictory. Unfortunately, these women face these issues at a key moment of there identity construction (self, relationship, sexuality) while they are not yet concerned by health prevention measures. A special psychoeducational intervention was designed to help these women to better cope with these difficulties. Intervention consists in a week-end session in a thermal center (SPA) during which they will attend short conferences given by specialists (prevention measures, prophylactic surgery, assisted procreation, epidemiology...) and participate to role games and group sharing. Intervention will be evaluated using self-questionnaires completed before intervention and during the following year.


Description:

Background: Young women exposed to a high hereditary breast/ovaries cancer (HBOC) risk are particularly vulnerable: they are ignored by health prevention measures; they are embedded in a stream of contradictory information ( medicine, media, internet); they may feel concerned by surgical prevention issues at a key moment of there identity construction (self, relationship, sexuality). A special psychoeducational intervention was designed to help these women to better cope with these difficulties. Methods/design: the study consists in a prospective randomized trial including childless young female counselees (18-40 years) of CCC Jean Perrin oncogenetics department, belonging to HBOC families either BRCA-mutated or not. They will be invited to attend a weekend group session in a SPA resort and participate to a series of short expert conferences and to focus group activities (group sharing, Moreno role game) supervised by a psychotherapist. Two sessions separated by a 6-month delay (waiting list) will enable us to evaluate the intervention effect, by comparing the evolution of questionnaires scores between inclusion and 6-month post-intervention. Main end-point is an increase of the Hert Hope Inventory of at least one standard deviation. Secondary endpoints investigate self-esteem, anxiety-trait, anxiety-state, ways of coping and quality of life. Participants will be randomized 1:1 to the first or the second session so that groups are comparable. Session will be cost-free for participants.


Recruitment information / eligibility

Status Terminated
Enrollment 32
Est. completion date September 14, 2021
Est. primary completion date September 14, 2021
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria: - Participants must belong to HBOC families, - aged between 18 and 40 years - Single or couple with a desire to have a child - without any personal history of cancer. - must have consulted at the oncogenetics department of the CCC Jean Perrin - tested for a BRCA mutation. - mutation carrier in case of a known familial BRCA mutation, else exposed to a high familial HBOC risk (Eisinger score = 6 or Manchester score = 16) - must live in Auvergne region (middle France) - signed an informed consent before inclusion. Exclusion Criteria: - pregnant women - person who cannot answer questionnaires: language difficulties and/or cannot write in French correctly. - no possible connection to our web-site - psychiatric troubles and/or ongoing treatments preventing from a week-end stay in a SPA resort

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
psychoeducation
Participants will attend conferences where experts present the state of the art in various domains: Latest knowledge in oncogenetics Recommendations and morbidity of prophylactic breast surgeries and annexectomy Epidemiology of HBOC and comparative mortality risks with other syndromes/life habits How to perform the periodic breast screening Assisted medical procreation and embryo selection Importance of nutrition and physical activity as risk modulator Life habits: how one can increase or lower the cancer risk (tobacco, alcohol...)? Description of the assistance program (GENAUV) to help counselees exposed to a high cancer risk follow their medical screening. The remaining time after this information, i.e. about half of the week-end, will comprise group activities, in particular role games (Moreno psychodrama approach) and group sharing under the supervision of a psychotherapist.

Locations

Country Name City State
France Centre Jean Perrin Clermont-Ferrand Puy De Dome

Sponsors (2)

Lead Sponsor Collaborator
Centre Jean Perrin Fondation de l'Avenir et la MASFIP, Paris - France

Country where clinical trial is conducted

France, 

References & Publications (9)

Bruchon-Schweitzer M, Cousson F, Quintard B, Nuissier J, Rascle N. French adaptation of the Ways of Coping Checklist. Percept Mot Skills. 1996 Aug;83(1):104-6. — View Citation

Cousson-Gélie F, Cosnefroy O, Christophe V, Segrestan-Crouzet C, Merckaert I, Fournier E, Libert Y, Lafaye A, Razavi D. The Ways of Coping Checklist (WCC): validation in French-speaking cancer patients. J Health Psychol. 2010 Nov;15(8):1246-56. doi: 10.1177/1359105310364438. Epub 2010 Aug 27. — View Citation

Folkman S, Lazarus RS. An analysis of coping in a middle-aged community sample. J Health Soc Behav. 1980 Sep;21(3):219-39. — View Citation

Herth K. Abbreviated instrument to measure hope: development and psychometric evaluation. J Adv Nurs. 1992 Oct;17(10):1251-9. — View Citation

Herth K. Enhancing hope in people with a first recurrence of cancer. J Adv Nurs. 2000 Dec;32(6):1431-41. — View Citation

Leplège A, Réveillère C, Ecosse E, Caria A, Rivière H. [Psychometric properties of a new instrument for evaluating quality of life, the WHOQOL-26, in a population of patients with neuromuscular diseases]. Encephale. 2000 Sep-Oct;26(5):13-22. French. — View Citation

Levenson H. Multidimensional locus of control in psychiatric patients. J Consult Clin Psychol. 1973 Dec;41(3):397-404. — View Citation

Loas G, Dardennes R, Dhee-Perot P, Leclerc V, Fremaux D. [Operationalization of the "locus of control" concept: translation and first validation study of the Levenson control scale (IPC: the internal powerful others and chance scale)]. Ann Med Psychol (Paris). 1994 Aug-Sep;152(7):466-9. French. — View Citation

Power M, Harper A, Bullinger M. The World Health Organization WHOQOL-100: tests of the universality of Quality of Life in 15 different cultural groups worldwide. Health Psychol. 1999 Sep;18(5):495-505. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary changes in expectations measured using the Hert Hope Inventory questionnaire Hert Hope Inventory global score [Herth, 1992, 2000] is used to evaluate expectations of participants. It contains only 12 simple proposals quoted using a 4-point Likert scale ranking from 1 = "strongly disagree" to 4 = "strongly agree". Its internal structure is composed of three dimensions: temporality and future, positive readiness and expectancy, and social/spiritual connectedness [Farran, 1995]. This questionnaire has been translated and validated in French by Lafrance [2013]. changes of global score from baseline to 6-month post-intervention.
Secondary Dimensions of coping evaluated by the Ways of Coping Checklist (WCC) [Folkman, 1980]. The WCC French version contains 27 items quoted by Likert scales (answers within "no", "rather no", "rather yes", "yes"). Three specific dimensions are described:
the focus on the problem
the focus on emotions
the search for social support Dimensions will be used separately using their scores as no global score can be calculated (dimensions are divergent). This questionnaire has been validated in French in 1996 by Bruchon-Schweitzer et al.
inclusion - 6-month post-intervention - 1-year post-intervention
Secondary Dimensions of perceived control measured using the Internal Powerful others and Chance scale (IPC) [Levenson, 1973]. Perceived Control of IPC tests two locus of control: either in the self, or outside with two origins: fate/luck and "powerful others". Scores qualifying each locus of control will be used for statistics. This 24-item scale has been validated in French by Loas et al. [1994]. inclusion - 6-month post-intervention - 1-year post-intervention
Secondary Level of Anxiety, either fundamental (as a trait of character) or superficial (depending on circumstances) evaluated by the State and Trait Anxiety Inventory (STAI A-B) [Spielberger, 1983] The STAI A-B questionnaire evaluates anxiety in a way it cannot be confused with depressive syndrome. It comprises 40 items rated on a 4-point scale from "almost never" to "almost always". The 20 first ones evaluate the anxiety as a state, that is a labile/contextual form. The last 20 items estimate anxiety as a personality trait, independent of the environment. It has been translated and validated in French by Schweitzer & Paulhan [1990]. inclusion - 6-month post-intervention - 1-year post-intervention
Secondary Score of the Self-Esteem Scale (SES) [Rosenberg, 1965] It is a short 10-item questionnaire that evaluates the global self-worth by questioning positive and negative feelings about the self. The uni-dimensionality of the scale has been validated [Gray-Little, 1997]. The global score of the scale will be used as an indicator of self-esteem. inclusion - 6-month post-intervention - 1-year post-intervention
Secondary Subscales and global score of the WHO Quality of life questionnaire ( World Health Organization WHOQOL) [Harper, 1998]. This questionnaire is worldwidely used. It contains four main dimensions: physical health, psychological, social relationships and environment. These dimensions have been confirmed in the French version by Leplège et al. [2000]. The global QoL score (means of subscales) will also be used for statistics. inclusion - 6-month post-intervention - 1-year post-intervention
See also
  Status Clinical Trial Phase
Completed NCT00535119 - Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer Phase 1
Recruiting NCT03294343 - Risk-Reducing Surgeries for Hereditary Ovarian Cancer N/A
Completed NCT02956681 - Statewide Communication to Reach Diverse Low Income Women N/A
Completed NCT00305695 - Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries Phase 2
Active, not recruiting NCT03832985 - Pediatric Reporting of Adult-Onset Genomic Results Early Phase 1
Active, not recruiting NCT02760849 - Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations N/A
Recruiting NCT02653105 - Women at Risk of Breast Cancer and OLFM4 N/A
Completed NCT01367639 - Trial of Inquiry Based Stress Reduction (IBSR) Program for BRCA1/2 Mutation Carriers Phase 2
Completed NCT02562170 - Protexa® Versus TiLoopBra® in Immediate Breast Reconstruction- A Pilot Study Phase 4
Recruiting NCT03162276 - Trial of Inquiry Based Stress Reduction (IBSR) Program for BRCA1/2 Mutation Carriers Phase 3
Not yet recruiting NCT01445275 - Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199 N/A
Recruiting NCT03015376 - Inherited Susceptible Genes Among Epithelial Ovarian Cancer
Enrolling by invitation NCT04197856 - Direct Information to At-risk Relatives N/A
Completed NCT03784859 - Tissue Expansion in Breast Reconstruction Without Drains
Completed NCT04544501 - Enhance the Use of Genetic Counseling and Testing in Latinas N/A
Completed NCT00609505 - Telemedicine vs. Face-to-Face Cancer Genetic Counseling N/A
Completed NCT01333748 - Search Allelic Imbalance of Expression of BRCA Genes in Hereditary Risk of Breast and/or Ovarian Cancer Phase 2
Completed NCT00892736 - Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy Phase 1
Recruiting NCT05677048 - Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention N/A